These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 31394199)

  • 1. Hemodynamic Effects of Pulmonary Arterial Hypertension-Specific Therapy in Patients With Heart Failure With Preserved Ejection Fraction and With Combined Post- and Precapillay Pulmonary Hypertension.
    Huis In't Veld AE; Oosterveer FPT; De Man FS; Marcus JT; Nossent EJ; Boonstra A; Van Rossum ACB; Vonk Noordegraaf A; Bogaard HJ; Handoko ML
    J Card Fail; 2020 Jan; 26(1):26-34. PubMed ID: 31394199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension.
    Patel RB; Li E; Benefield BC; Swat SA; Polsinelli VB; Carr JC; Shah SJ; Markl M; Collins JD; Freed BH
    ESC Heart Fail; 2020 Feb; 7(1):253-263. PubMed ID: 31903694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiomics features of the cardiac blood pool to indicate hemodynamic changes in pulmonary hypertension (PH) due to heart failure with preserved ejection fraction (PH-HFpEF).
    Lin K; Sarnari R; Gordon DZ; Markl M; Carr JC
    Int J Cardiovasc Imaging; 2024 Jul; 40(7):1501-1509. PubMed ID: 38801547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Right Ventricular and Right Atrial Function Are Less Compromised in Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction: A Comparison With Pulmonary Arterial Hypertension With Similar Pressure Overload.
    van Wezenbeek J; Kianzad A; van de Bovenkamp A; Wessels J; Mouratoglou SA; Braams NJ; Jansen SMA; Meulblok E; Meijboom LJ; Marcus JT; Vonk Noordegraaf A; José Goumans M; Jan Bogaard H; Handoko ML; de Man FS
    Circ Heart Fail; 2022 Feb; 15(2):e008726. PubMed ID: 34937392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wedge Pressure Rather Than Left Ventricular End-Diastolic Pressure Predicts Outcome in Heart Failure With Preserved Ejection Fraction.
    Mascherbauer J; Zotter-Tufaro C; Duca F; Binder C; Koschutnik M; Kammerlander AA; Aschauer S; Bonderman D
    JACC Heart Fail; 2017 Nov; 5(11):795-801. PubMed ID: 29032138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.
    Guazzi M; Vicenzi M; Arena R; Guazzi MD
    Circulation; 2011 Jul; 124(2):164-74. PubMed ID: 21709061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cine MRI characterizes HFpEF and HFrEF in post-capillary pulmonary hypertension.
    Lin K; Sarnari R; Pathrose A; Gordon DZ; Blaisdell J; Markl M; Carr JC
    Eur J Radiol; 2021 Jun; 139():109679. PubMed ID: 33819807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Simple Derived Prediction Score for the Identification of an Elevated Pulmonary Artery Wedge Pressure Using Precatheterization Clinical Data in Patients Referred to a Pulmonary Hypertension Center.
    Richter SE; Roberts KE; Preston IR; Hill NS
    Chest; 2016 May; 149(5):1261-8. PubMed ID: 26501213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced pulmonary vasodilator reserve and abnormal right ventricular: pulmonary artery coupling in heart failure with preserved ejection fraction.
    Andersen MJ; Hwang SJ; Kane GC; Melenovsky V; Olson TP; Fetterly K; Borlaug BA
    Circ Heart Fail; 2015 May; 8(3):542-50. PubMed ID: 25857307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic hypertension in low-gradient severe aortic stenosis with preserved ejection fraction.
    Eleid MF; Nishimura RA; Sorajja P; Borlaug BA
    Circulation; 2013 Sep; 128(12):1349-53. PubMed ID: 23956211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
    Kramer T; Dumitrescu D; Gerhardt F; Orlova K; Ten Freyhaus H; Hellmich M; Baldus S; Rosenkranz S
    Int J Cardiol; 2019 May; 283():152-158. PubMed ID: 30777406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction.
    Vanderpool RR; Saul M; Nouraie M; Gladwin MT; Simon MA
    JAMA Cardiol; 2018 Apr; 3(4):298-306. PubMed ID: 29541759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of left ventricular diastolic function profile in patients with pulmonary hypertension due to heart failure with preserved ejection fraction.
    Raeisi-Giglou P; Lam L; Tamarappoo BK; Newman J; Dweik RA; Tonelli AR
    Clin Cardiol; 2017 Jun; 40(6):356-363. PubMed ID: 28026030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension.
    Verbrugge FH; Dupont M; Bertrand PB; Nijst P; Grieten L; Dens J; Verhaert D; Janssens S; Tang WH; Mullens W
    Eur J Heart Fail; 2015 Mar; 17(3):320-8. PubMed ID: 25639263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhaled nitric oxide testing in predicting prognosis in pulmonary hypertension due to left-sided heart diseases.
    Satoh T; Yaoita N; Nochioka K; Tatebe S; Hayashi H; Yamamoto S; Sato H; Takahama H; Suzuki H; Terui Y; Yamada K; Yamada Y; Inoue T; Aoki T; Satoh K; Sugimura K; Miyata S; Yasuda S
    ESC Heart Fail; 2023 Dec; 10(6):3592-3603. PubMed ID: 37775984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction.
    Simon MA; Vanderpool RR; Nouraie M; Bachman TN; White PM; Sugahara M; Gorcsan J; Parsley EL; Gladwin MT
    JCI Insight; 2016 Nov; 1(18):e89620. PubMed ID: 27812547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
    Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of right ventricular dysfunction on the effectiveness of beta-blockers in heart failure with preserved ejection fraction.
    Harada D; Asanoi H; Noto T; Takagawa J
    J Cardiol; 2020 Oct; 76(4):325-334. PubMed ID: 32475652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Inhaled Nitric Oxide Response Predict Tolerance to Therapies and Survival in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension?
    Krishtopaytis E; Ampnti SA; Obeidat M; Ramahi N; Lane J; Toth D; Paul D; Tonelli AR
    Am J Cardiol; 2023 Nov; 207():363-369. PubMed ID: 37778225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RV Contractile Function and its Coupling to Pulmonary Circulation in Heart Failure With Preserved Ejection Fraction: Stratification of Clinical Phenotypes and Outcomes.
    Guazzi M; Dixon D; Labate V; Beussink-Nelson L; Bandera F; Cuttica MJ; Shah SJ
    JACC Cardiovasc Imaging; 2017 Oct; 10(10 Pt B):1211-1221. PubMed ID: 28412423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.